At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 641 enrolled
Drug / intervention
sitagliptin phosphate +1 moredrug
Likely dose
sitagliptin phosphate 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III, Multicenter, Randomized, Double-Blind Clinical Trial to Study the Safety and Efficacy of the Addition of Sitagliptin (MK0431) to Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Insulin Therapy (Alone or In Combination With Metformin)
In Brief
A Phase 3 clinical trial evaluating sitagliptin phosphate and Comparator : placebo (unspecified) for Type 2 Diabetes Mellitus. Completed, enrolled 641 participants.
Detailed Summary
A clinical study to determine the safety and efficacy of sitagliptin in patients with Type 2 Diabetes Mellitus who have inadequate glycemic control on insulin or insulin/metformin combination therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 2006
Enrollment StartDec 2006
Primary CompletionOct 2008
TodayJul 2026
First PostedNov 2, 2006
Enrollment StartDec 11, 2006
Primary CompletionOct 13, 2008
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 19.7 years ago
Interventions
sitagliptin phosphatedrug
sitagliptin 100 mg tablet qd for a 24-wk treatment period.
Comparator : placebo (unspecified)drug
sitagliptin 100 mg Pbo tablet qd for a 24-wk treatment period.